Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today ...
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib – a targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results